Upstream Bio (UPB) Stock Price, News & Analysis

Company Overview

Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing therapies for inflammatory and immune-mediated diseases. The company’s research is centered on targeting pathways involved in type 2 inflammation, which contributes to conditions affecting the respiratory system and other tissues.

Its lead product candidate is verekitug, an investigational, long-acting monoclonal antibody designed to block thymic stromal lymphopoietin (TSLP), an epithelial cytokine that plays a role in initiating and maintaining allergic and inflammatory responses. Upstream Bio is evaluating verekitug in conditions including asthma and chronic rhinosinusitis with nasal polyps.

Upstream Bio was established to advance medicines for patients whose inflammatory diseases remain inadequately controlled by existing treatments. The company is headquartered in the United States and is conducting clinical development activities through research and trial programs focused primarily on immune-mediated respiratory diseases.

Key Stats

• Today's Range: $3.33 to $3.66
• 50-Day Range: $2.74 to $6.62
• 52-Week Range: $2.68 to $33.68
• Volume: 99,708 shs
• Average Volume: 884,754 shs
• Market Capitalization: $189.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $29.67
• Consensus Rating: Hold

Upstream Bio Stock Analysis - MarketRank™

Upstream Bio scored higher than 76% of companies evaluated by MarketBeat, and ranked 184th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

Upstream Bio has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Upstream Bio has a consensus price target of $29.67, representing about 717.3% upside from its current price of $3.63.

Amount of Analyst Coverage

Upstream Bio has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Upstream Bio are expected to grow in the coming year, from ($2.84) to ($2.77) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Upstream Bio is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Upstream Bio is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Upstream Bio has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.79% of the float of Upstream Bio has been sold short.

Short Interest Ratio / Days to Cover

Upstream Bio has a short interest ratio ("days to cover") of 3.69, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Upstream Bio has recently decreased by 0.75%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Upstream Bio does not currently pay a dividend.

Dividend Growth

Upstream Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 4.4 / 5
• News Sentiment: 1.02

News Sentiment

Upstream Bio has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Upstream Bio this week, compared to 2 articles on an average week.

Search Interest

4 people have searched for UPB on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Upstream Bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Upstream Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.46% of the stock of Upstream Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Upstream Bio has minimal institutional ownership at this time.

Company Calendar

• Today: 11/10/2026
• Last Earnings: 11/10/2026
• Next Earnings (Estimated): 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:UPB
• Previous Symbol: NASDAQ:UPB
• CIK: 2022626
• Web: upstreambio.com
• Phone: (781) 208-2466
• Fax: N/A
• Employees: 75
• Year Founded: 2021

Price Target and Rating

• Average Price Target for Upstream Bio: $29.67
• High Price Target: $50.00
• Low Price Target: $9.00
• Potential Upside/Downside: +717.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$143.44 million
• Net Margins: -4,955.67%
• Pretax Margin: -4,955.67%
• Return on Equity: -48.40%
• Return on Assets: -46.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 27.99
• Quick Ratio: 27.99

Sales & Book Value

• Annual Sales: $2.85 million
• Price / Sales: 69.76
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.29 per share
• Price / Book: 0.58

Miscellaneous

• Outstanding Shares: 54,770,000
• Free Float: 45,756,000
• Market Cap: $198.82 million
• Optionable: Optionable
• Beta: 1.60